Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-TTR Polyclonal Antibody

Catalog #:   PHC01301 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: P02766
Overview

Catalog No.

PHC01301

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human TTR (Gly21-Glu147).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Transthyretin,Prealbumin,TBPA,TTR,PALB,ATTR

Purification

Purified by antigen affinity column.

Accession

P02766

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with TTR antibody (PHC01301) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 16 kDa
    Observed MW: 16 kDa
References

An Enhanced Diagnostic Model for Incidental Hashimoto's Thyroiditis Using T2-Weighted and Diffusion-Weighted Imaging., PMID:40450387

Intracellular and Extracellular Localization of Transthyretin and Its Association With Amyloid-β in Alzheimer's Disease Brains., PMID:40448526

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going., PMID:40429476

Current and emerging treatment options for transthyretin amyloid cardiomyopathy., PMID:40425273

Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy., PMID:40335224

Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy., PMID:40332772

Unraveling the Serum Protein Landscape in Celiac Disease: Current Evidence and Future Directions., PMID:40325942

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial., PMID:40325445

Wastewater surveillance for Salmonella Typhi and its association with seroincidence of enteric fever in Vellore, India., PMID:40029872

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study., PMID:40025610

Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)., PMID:39928315

Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies., PMID:39841315

Enhanced activity of autoimmune gastritis following Helicobacter pylori eradication therapy., PMID:39806234

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population., PMID:39805350

Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation., PMID:39775625

Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis., PMID:39627935

Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022., PMID:39592278

Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances., PMID:39551565

PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study., PMID:39472768

Safety and efficacy of tisotumab vedotin with cervical cancers: A systematic review and meta-analysis., PMID:39428336

Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy., PMID:39376580

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis., PMID:39338387

Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes., PMID:39123482

Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients., PMID:39029855

Immunohistochemical Diagnosis of Amyloid Typing: Utility and Limitations as Determined by Liquid Chromatography-Tandem Mass Spectrometry., PMID:38972738

Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis., PMID:38923548

Evaluation of thyroid-disrupting effects of bisphenol F and bisphenol S on zebrafish (Danio rerio) using anti-transthyretin monoclonal antibody-based immunoassays., PMID:38851028

Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience., PMID:38805036

Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis., PMID:38801321

Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development of De Novo Donor-specific Antibodies., PMID:38694489

Treatment of transthyretin cardiac amyloidosis., PMID:38652263

PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guérin (BCG) Therapy., PMID:38611034

Scleritis following intravitreal brolucizumab injection: a case series., PMID:38419100

Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study., PMID:38387261

Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer., PMID:38359019

Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study., PMID:38286887

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy., PMID:38233673

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study., PMID:38217945

Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment., PMID:38111336

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial., PMID:37942328

Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case., PMID:37927586

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation., PMID:37639169

Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastases., PMID:37501197

Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures., PMID:37439769

Treatment of amyloidosis: present and future., PMID:37091663

[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]., PMID:37078218

Evaluation of fetal thymus size in maternal autoimmune diseases: systemic lupus erythematosus, Sjögren's syndrome and antiphospholipid antibody syndrome., PMID:37037914

Neoadjuvant treatment for stage III and IV cutaneous melanoma., PMID:36648215

Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination., PMID:36644001

Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial., PMID:36535121

Datasheet

Document Download

Anti-TTR Polyclonal Antibody.pdf

 

$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-TTR Polyclonal Antibody [PHC01301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only